Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-02-09

AUTHORS

Hiroyoshi Yokoi, Eisei Oda, Kazuki Kaneko, Kenta Matsubayashi

ABSTRACT

In this real-world, retrospective cohort study of 9753 patients in Japan prescribed dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), we investigated DAPT duration and determined factors associated with early DAPT discontinuation and with event rates in patients who discontinued DAPT. The study period was April 1, 2012–March 31, 2018; endpoints comprised composite efficacy [death, myocardial infarction (MI), and stroke] and bleeding (intracranial, gastrointestinal, and requiring transfusion) endpoints. Overall, 68.8% of patients were continuing DAPT at 3 months post-PCI. Patients without major efficacy or safety events within 3 months after index PCI were included in a landmark analysis set (LAS; n = 7056), and categorized as DAPT ≥ 3 months (continuation) versus < 3 months (discontinuation). In the two LAS analysis groups, there was no difference in the composite bleeding endpoint (P = 0.067), although the incidence of the composite efficacy endpoint was higher in the discontinuation group (P < 0.001). In multivariate regression analysis, age ≥ 75 years, minor bleeding after PCI, history of cerebral infarction, history of cerebral or gastrointestinal bleeding, atrial fibrillation, dialysis, and anticoagulant use after PCI were associated with early DAPT discontinuation. Acute coronary syndrome, history of MI, kidney disorder, and anticoagulant use after PCI were associated with the composite efficacy endpoint in the discontinuation group. In conclusion, early DAPT discontinuation is more likely in patients at high bleeding risk, but may influence the occurrence of ischemic events in these patients. Determination of DAPT duration should take into account potential ischemic risk, even in patients at high bleeding risk. More... »

PAGES

465-474

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12928-021-00833-z

DOI

http://dx.doi.org/10.1007/s12928-021-00833-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1145403453

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35141843


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticoagulants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gastrointestinal Hemorrhage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hospitals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myocardial Infarction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Percutaneous Coronary Intervention", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Aggregation Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "International University of Health and Welfare, Tochigi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411731.1", 
          "name": [
            "Cardiovascular Medicine Center, Fukuoka Sanno Hospital, 3-6-45 Momochihama, Sawara-ku, 814-0001, Fukuoka, Japan", 
            "International University of Health and Welfare, Tochigi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yokoi", 
        "givenName": "Hiroyoshi", 
        "id": "sg:person.01052603744.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052603744.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "StatLink Medical Statistics Consulting Service, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "StatLink Medical Statistics Consulting Service, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oda", 
        "givenName": "Eisei", 
        "id": "sg:person.016464605275.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016464605275.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EBM Unit, Medical Data Vision Co., Ltd., Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EBM Unit, Medical Data Vision Co., Ltd., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaneko", 
        "givenName": "Kazuki", 
        "id": "sg:person.013473141311.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013473141311.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Development Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410844.d", 
          "name": [
            "Clinical Development Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsubayashi", 
        "givenName": "Kenta", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00392-020-01708-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1129531993", 
          "https://doi.org/10.1007/s00392-020-01708-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrcardio.2014.104", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039569766", 
          "https://doi.org/10.1038/nrcardio.2014.104"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11239-018-1707-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105133084", 
          "https://doi.org/10.1007/s11239-018-1707-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-02-09", 
    "datePublishedReg": "2022-02-09", 
    "description": "In this real-world, retrospective cohort study of 9753 patients in Japan prescribed dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), we investigated DAPT duration and determined factors associated with early DAPT discontinuation and with event rates in patients who discontinued DAPT. The study period was April 1, 2012\u2013March 31, 2018; endpoints comprised composite efficacy [death, myocardial infarction (MI), and stroke] and bleeding (intracranial, gastrointestinal, and requiring transfusion) endpoints. Overall, 68.8% of patients were continuing DAPT at 3\u00a0months post-PCI. Patients without major efficacy or safety events within 3\u00a0months after index PCI were included in a landmark analysis set (LAS; n\u2009=\u20097056), and categorized as DAPT\u2009\u2265\u20093\u00a0months (continuation) versus\u2009<\u20093\u00a0months (discontinuation). In the two LAS analysis groups, there was no difference in the composite bleeding endpoint (P\u2009=\u20090.067), although the incidence of the composite efficacy endpoint was higher in the discontinuation group (P\u2009<\u20090.001). In multivariate regression analysis, age\u2009\u2265\u200975\u00a0years, minor bleeding after PCI, history of cerebral infarction, history of cerebral or gastrointestinal bleeding, atrial fibrillation, dialysis, and anticoagulant use after PCI were associated with early DAPT discontinuation. Acute coronary syndrome, history of MI, kidney disorder, and anticoagulant use after PCI were associated with the composite efficacy endpoint in the discontinuation group. In conclusion, early DAPT discontinuation is more likely in patients at high bleeding risk, but may influence the occurrence of ischemic events in these patients. Determination of DAPT duration should take into account potential ischemic risk, even in patients at high bleeding risk.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12928-021-00833-z", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1042779", 
        "issn": [
          "1868-4300", 
          "1868-4297"
        ], 
        "name": "Cardiovascular Intervention and Therapeutics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "37"
      }
    ], 
    "keywords": [
      "dual antiplatelet therapy", 
      "percutaneous coronary intervention", 
      "composite efficacy endpoint", 
      "high bleeding risk", 
      "retrospective cohort study", 
      "DAPT discontinuation", 
      "antiplatelet therapy", 
      "discontinuation group", 
      "DAPT duration", 
      "efficacy endpoint", 
      "bleeding risk", 
      "cohort study", 
      "coronary intervention", 
      "anticoagulant use", 
      "index percutaneous coronary intervention", 
      "acute coronary syndrome", 
      "history of MI", 
      "multivariate regression analysis", 
      "medical information database", 
      "ischemic risk", 
      "minor bleeding", 
      "gastrointestinal bleeding", 
      "coronary syndrome", 
      "cerebral infarction", 
      "ischemic events", 
      "major efficacy", 
      "clinical outcomes", 
      "atrial fibrillation", 
      "landmark analysis", 
      "patients", 
      "kidney disorders", 
      "composite efficacy", 
      "Japanese hospitals", 
      "discontinuation", 
      "event rates", 
      "study period", 
      "safety events", 
      "endpoint", 
      "months", 
      "bleeding", 
      "regression analysis", 
      "therapy", 
      "risk", 
      "efficacy", 
      "duration", 
      "intervention", 
      "determined factors", 
      "group", 
      "analysis group", 
      "infarction", 
      "fibrillation", 
      "syndrome", 
      "hospital", 
      "incidence", 
      "dialysis", 
      "information database", 
      "history", 
      "disorders", 
      "age", 
      "outcomes", 
      "study", 
      "conclusion", 
      "events", 
      "MI", 
      "years", 
      "use", 
      "period", 
      "factors", 
      "differences", 
      "database", 
      "occurrence", 
      "rate", 
      "analysis", 
      "Japan", 
      "determination"
    ], 
    "name": "Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information database from Japanese hospitals", 
    "pagination": "465-474", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1145403453"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12928-021-00833-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35141843"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12928-021-00833-z", 
      "https://app.dimensions.ai/details/publication/pub.1145403453"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_943.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12928-021-00833-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12928-021-00833-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12928-021-00833-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12928-021-00833-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12928-021-00833-z'


 

This table displays all metadata directly associated to this object as RDF triples.

225 TRIPLES      21 PREDICATES      115 URIs      104 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12928-021-00833-z schema:about N127b549f958a4937a8af1411f8e907fd
2 N14dc73c3299a4cb1a6e516cc63250002
3 N4d88337400f04a559d4cb031fe90dddb
4 N68990daa62604dca95141bb99991bc2c
5 N72b1e5236c6a49eabc09233ddefa1d8e
6 N7a0ba6ba41c741fcb6a595aea206d231
7 N7d49ea70ec314bd780db43404c4fe49a
8 N96447798fd13463084af5acf44f154fe
9 N997065933f9d4dffa471aa2d986dcb95
10 Nb323261a99cc4af681d0b7ef2c0a556f
11 Ne07298b8bece4fe1a40ad0a62771a634
12 Necd8bea8feac4fee99a84d834eb41ca2
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author N531e6e9593c6462eb3df25acad6e92f1
16 schema:citation sg:pub.10.1007/s00392-020-01708-8
17 sg:pub.10.1007/s11239-018-1707-1
18 sg:pub.10.1038/nrcardio.2014.104
19 schema:datePublished 2022-02-09
20 schema:datePublishedReg 2022-02-09
21 schema:description In this real-world, retrospective cohort study of 9753 patients in Japan prescribed dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), we investigated DAPT duration and determined factors associated with early DAPT discontinuation and with event rates in patients who discontinued DAPT. The study period was April 1, 2012–March 31, 2018; endpoints comprised composite efficacy [death, myocardial infarction (MI), and stroke] and bleeding (intracranial, gastrointestinal, and requiring transfusion) endpoints. Overall, 68.8% of patients were continuing DAPT at 3 months post-PCI. Patients without major efficacy or safety events within 3 months after index PCI were included in a landmark analysis set (LAS; n = 7056), and categorized as DAPT ≥ 3 months (continuation) versus < 3 months (discontinuation). In the two LAS analysis groups, there was no difference in the composite bleeding endpoint (P = 0.067), although the incidence of the composite efficacy endpoint was higher in the discontinuation group (P < 0.001). In multivariate regression analysis, age ≥ 75 years, minor bleeding after PCI, history of cerebral infarction, history of cerebral or gastrointestinal bleeding, atrial fibrillation, dialysis, and anticoagulant use after PCI were associated with early DAPT discontinuation. Acute coronary syndrome, history of MI, kidney disorder, and anticoagulant use after PCI were associated with the composite efficacy endpoint in the discontinuation group. In conclusion, early DAPT discontinuation is more likely in patients at high bleeding risk, but may influence the occurrence of ischemic events in these patients. Determination of DAPT duration should take into account potential ischemic risk, even in patients at high bleeding risk.
22 schema:genre article
23 schema:isAccessibleForFree true
24 schema:isPartOf N5905a354b07e47a5b4dc3200a9775095
25 Nde7e85c6794247b6a823edeb421a22dd
26 sg:journal.1042779
27 schema:keywords DAPT discontinuation
28 DAPT duration
29 Japan
30 Japanese hospitals
31 MI
32 acute coronary syndrome
33 age
34 analysis
35 analysis group
36 anticoagulant use
37 antiplatelet therapy
38 atrial fibrillation
39 bleeding
40 bleeding risk
41 cerebral infarction
42 clinical outcomes
43 cohort study
44 composite efficacy
45 composite efficacy endpoint
46 conclusion
47 coronary intervention
48 coronary syndrome
49 database
50 determination
51 determined factors
52 dialysis
53 differences
54 discontinuation
55 discontinuation group
56 disorders
57 dual antiplatelet therapy
58 duration
59 efficacy
60 efficacy endpoint
61 endpoint
62 event rates
63 events
64 factors
65 fibrillation
66 gastrointestinal bleeding
67 group
68 high bleeding risk
69 history
70 history of MI
71 hospital
72 incidence
73 index percutaneous coronary intervention
74 infarction
75 information database
76 intervention
77 ischemic events
78 ischemic risk
79 kidney disorders
80 landmark analysis
81 major efficacy
82 medical information database
83 minor bleeding
84 months
85 multivariate regression analysis
86 occurrence
87 outcomes
88 patients
89 percutaneous coronary intervention
90 period
91 rate
92 regression analysis
93 retrospective cohort study
94 risk
95 safety events
96 study
97 study period
98 syndrome
99 therapy
100 use
101 years
102 schema:name Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information database from Japanese hospitals
103 schema:pagination 465-474
104 schema:productId N1c4f60f8a6684fe293dc72bc343da305
105 Na1e269b0644f481e9ca7683892fcea91
106 Nd2bc8d5efcb24613a7760f79f8f34872
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1145403453
108 https://doi.org/10.1007/s12928-021-00833-z
109 schema:sdDatePublished 2022-10-01T06:50
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher Nc7a853cb703643cd9fa344baa4adeb4a
112 schema:url https://doi.org/10.1007/s12928-021-00833-z
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N127b549f958a4937a8af1411f8e907fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Retrospective Studies
118 rdf:type schema:DefinedTerm
119 N14dc73c3299a4cb1a6e516cc63250002 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Aged
121 rdf:type schema:DefinedTerm
122 N17bbee77d00a43ca966e7f07b811db9b rdf:first Ndf44ac5e616e4eee83e4dca9324ef55b
123 rdf:rest rdf:nil
124 N1c4f60f8a6684fe293dc72bc343da305 schema:name pubmed_id
125 schema:value 35141843
126 rdf:type schema:PropertyValue
127 N4d88337400f04a559d4cb031fe90dddb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Gastrointestinal Hemorrhage
129 rdf:type schema:DefinedTerm
130 N531e6e9593c6462eb3df25acad6e92f1 rdf:first sg:person.01052603744.16
131 rdf:rest Nc2ffa51333f9450f961539efaf1afe3e
132 N5905a354b07e47a5b4dc3200a9775095 schema:volumeNumber 37
133 rdf:type schema:PublicationVolume
134 N68990daa62604dca95141bb99991bc2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Myocardial Infarction
136 rdf:type schema:DefinedTerm
137 N7126a64e80b44b27ad86a9748c67477e rdf:first sg:person.013473141311.02
138 rdf:rest N17bbee77d00a43ca966e7f07b811db9b
139 N72b1e5236c6a49eabc09233ddefa1d8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Japan
141 rdf:type schema:DefinedTerm
142 N7a0ba6ba41c741fcb6a595aea206d231 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Platelet Aggregation Inhibitors
144 rdf:type schema:DefinedTerm
145 N7d49ea70ec314bd780db43404c4fe49a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Anticoagulants
147 rdf:type schema:DefinedTerm
148 N96447798fd13463084af5acf44f154fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Hospitals
150 rdf:type schema:DefinedTerm
151 N997065933f9d4dffa471aa2d986dcb95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Humans
153 rdf:type schema:DefinedTerm
154 Na1e269b0644f481e9ca7683892fcea91 schema:name doi
155 schema:value 10.1007/s12928-021-00833-z
156 rdf:type schema:PropertyValue
157 Nb323261a99cc4af681d0b7ef2c0a556f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Treatment Outcome
159 rdf:type schema:DefinedTerm
160 Nc2ffa51333f9450f961539efaf1afe3e rdf:first sg:person.016464605275.48
161 rdf:rest N7126a64e80b44b27ad86a9748c67477e
162 Nc7a853cb703643cd9fa344baa4adeb4a schema:name Springer Nature - SN SciGraph project
163 rdf:type schema:Organization
164 Nd2bc8d5efcb24613a7760f79f8f34872 schema:name dimensions_id
165 schema:value pub.1145403453
166 rdf:type schema:PropertyValue
167 Nde7e85c6794247b6a823edeb421a22dd schema:issueNumber 3
168 rdf:type schema:PublicationIssue
169 Ndf44ac5e616e4eee83e4dca9324ef55b schema:affiliation grid-institutes:grid.410844.d
170 schema:familyName Matsubayashi
171 schema:givenName Kenta
172 rdf:type schema:Person
173 Ne07298b8bece4fe1a40ad0a62771a634 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Percutaneous Coronary Intervention
175 rdf:type schema:DefinedTerm
176 Necd8bea8feac4fee99a84d834eb41ca2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Drug Therapy, Combination
178 rdf:type schema:DefinedTerm
179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
180 schema:name Medical and Health Sciences
181 rdf:type schema:DefinedTerm
182 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
183 schema:name Clinical Sciences
184 rdf:type schema:DefinedTerm
185 sg:journal.1042779 schema:issn 1868-4297
186 1868-4300
187 schema:name Cardiovascular Intervention and Therapeutics
188 schema:publisher Springer Nature
189 rdf:type schema:Periodical
190 sg:person.01052603744.16 schema:affiliation grid-institutes:grid.411731.1
191 schema:familyName Yokoi
192 schema:givenName Hiroyoshi
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052603744.16
194 rdf:type schema:Person
195 sg:person.013473141311.02 schema:affiliation grid-institutes:None
196 schema:familyName Kaneko
197 schema:givenName Kazuki
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013473141311.02
199 rdf:type schema:Person
200 sg:person.016464605275.48 schema:affiliation grid-institutes:None
201 schema:familyName Oda
202 schema:givenName Eisei
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016464605275.48
204 rdf:type schema:Person
205 sg:pub.10.1007/s00392-020-01708-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1129531993
206 https://doi.org/10.1007/s00392-020-01708-8
207 rdf:type schema:CreativeWork
208 sg:pub.10.1007/s11239-018-1707-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105133084
209 https://doi.org/10.1007/s11239-018-1707-1
210 rdf:type schema:CreativeWork
211 sg:pub.10.1038/nrcardio.2014.104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039569766
212 https://doi.org/10.1038/nrcardio.2014.104
213 rdf:type schema:CreativeWork
214 grid-institutes:None schema:alternateName EBM Unit, Medical Data Vision Co., Ltd., Tokyo, Japan
215 StatLink Medical Statistics Consulting Service, Tokyo, Japan
216 schema:name EBM Unit, Medical Data Vision Co., Ltd., Tokyo, Japan
217 StatLink Medical Statistics Consulting Service, Tokyo, Japan
218 rdf:type schema:Organization
219 grid-institutes:grid.410844.d schema:alternateName Clinical Development Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan
220 schema:name Clinical Development Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan
221 rdf:type schema:Organization
222 grid-institutes:grid.411731.1 schema:alternateName International University of Health and Welfare, Tochigi, Japan
223 schema:name Cardiovascular Medicine Center, Fukuoka Sanno Hospital, 3-6-45 Momochihama, Sawara-ku, 814-0001, Fukuoka, Japan
224 International University of Health and Welfare, Tochigi, Japan
225 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...